Angiogenic and Lymphangiogenic Molecules in Hematological Malignancies

@article{Orpana2002AngiogenicAL,
  title={Angiogenic and Lymphangiogenic Molecules in Hematological Malignancies},
  author={Arto K. Orpana and Petri Salv{\'e}n},
  journal={Leukemia \& Lymphoma},
  year={2002},
  volume={43},
  pages={219 - 224}
}
In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of angiogenic polypeptides vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) associate with clinical characteristics in human leukemia and lymphoma… 
Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response
TLDR
There were significant decreases of VEGF and HGF levels and a significant increase in TSP-1 concentrations in the bone marrow plasma of patients who achieved complete or very good partial response in contrast to those who had partial or no response.
Clinical Role of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia
TLDR
The data suggest that the increased levels of VEGF and bFGF in bone marrow may play an important role in prognosis of childhood ALL.
Lymphangiogenesis and tumor metastasis.
TLDR
In several human cancers, increased expression in primary tumors of vascular endothelial growth factor-C (VEGF-C) is correlated with regional lymph node metastasis, which suggests that VEGF-C may serve functions other than lymphangiogenesis.
MMP13 Regulates Aggressiveness of Pediatric Multiple Myeloma Through VEGF-C
TLDR
The data suggest that MMP13 may activate VEGF-C to promote cancer cell metastasis through lymphatic vascular systems in pediatric MM.
Circulating angiogenic cytokines in multiple myeloma and related disorders.
TLDR
A strong relationship between angiogenic cytokine serum levels and clinical course as well as selected laboratory parameters of patients with multiple myeloma is indicated.
Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies.
TLDR
There is a need for additional methods that allow the estimation of ongoing angiogenesis in patients with multiple myeloma, and double immunostainings for CD34 and Ki-67 can be used on paraffin-embedded tissue to determine the endothelial proliferation fraction.
Lymphangiogenesis and tumor metastasis
TLDR
There is at present little evidence for lymphangiogenesis in human tumors and the relative importance of preexisting vs. newly formed lymphatics for metastasis in humans remains to be determined, but the striking correlation between the levels of VEGF-C in primary human tumor tumors and lymph node metastases predicts its importance in cancer spread.
Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia
TLDR
The findings indicate that the bone marrow microenvironment in MDS’→ OL and de novo AML differs remarkably, suggesting the different efficacy of anti‐angiogenic therapy between de noVO AML and leukaemia secondary to MDS.
...
...

References

SHOWING 1-10 OF 81 REFERENCES
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.
TLDR
The data suggest that vascularity and angiogenic factors are increased in leukemias and MDS and may play a role in theLeukemogenic process.
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
TLDR
The results raise the possibility that VEGF may play a role in the growth of hematopoietic neoplasms such as multiple myeloma through either a paracrine or an autocrine mechanism.
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.
TLDR
The effects of VEGF on marrow stroma are studied, focusing on the secretion of interleukin-6 (IL-6), a potent growth factor for myeloma cells and an inhibitor of plasma cell apoptosis, which suggests paracrine interactions between myelomas and marrow stromal cells triggered by VEGf and IL-6.
Expression of vascular endothelial growth factor in lymphomas and castleman's disease
TLDR
It is concluded that VEGF may be involved in the induction of the angiogenesis of both peripheral T‐cell lymphomas and Hodgkin's disease, but not in low‐grade B‐ cell lymphomas.
Angiogenic growth factors and endostatin in non‐Hodgkin's lymphoma
TLDR
The data suggest that b‐FGF and, particularly, VEGF might be considered prognostic factors in NHL staging and management.
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration.
TLDR
It is demonstrated that certain leukemias not only produce VEGF but also express functional VEGFR-2 in vivo and in vitro, resulting in the generation of an autocrine loop that may support leukemic cell survival and proliferation.
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.
TLDR
Investigation of expression of VEGF and its receptors on fresh leukemic blasts of AML blasts found a dose-dependent increase of granulocyte-macrophage colony-stimulating factor secretion from endothelial cells was identified.
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
TLDR
The results suggest that at least in AML patients with higher WBC and blast counts, cellular VEGF level is an independent predictor of outcome.
Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
TLDR
The potentials, limitations, and challenges within this field of research are discussed, in light of the development of new therapeutic strategies for diseases in which angiogenesis plays an important role.
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.
TLDR
There is evidence of increased microvessel density in the bone marrow of patients with AML, which supports the hypothesis of an important role of angiogenesis in AML and suggests that antiangiogenic therapy might constitute a novel strategy for the treatment of AML.
...
...